Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention
NCT ID: NCT07276763
Last Updated: 2025-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
16509 participants
OBSERVATIONAL
2025-12-10
2025-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound
NCT07251803
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying
NCT07140289
Investigation of the Evolution of Gastric Emptying by Gastric Ultra Sonography in Patients Treated With GLP-1 Receptor Agonists on a 7 Days Pausing Period.
NCT06388213
Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
NCT07297238
Effects of Beginning a GLP1-Agonist Therapy on Residual Gastric Content and Gastric Emptying
NCT06659159
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Using the electronic medical record system of Huadong Hospital, this retrospective study analyzed patients who underwent upper endoscopy between August 2023 and May 2025 to examine the association between different GLP-1RA exposure patterns and the risk of RGC, providing evidence to inform optimization of pre-procedural discontinuation strategies.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No GLP-1RA group
Patients with no prescription record of GLP-1RAs, or whose most recent prescription was more than 3 months before the EGD
No Intervention: Observational Cohort
No Intervention: Observational Cohort
GLP-1RA Continued group
Patients who met both of the following criteria:
1. Continued use of a GLP-1RA (e.g., semaglutide or dulaglutide) within 3 months prior to EGD;
2. Underwent painless EGD before August 2024, when our institution had not yet implemented restrictions on GLP-1RA use for painless endoscopy.
No Intervention: Observational Cohort
No Intervention: Observational Cohort
GLP-1RA Held 2 Weeks group
Patients who met both of the following criteria:
1. Continued use of a GLP-1RA (e.g., semaglutide or dulaglutide) within 3 months prior to EGD;
2. Underwent painless EGD after August 2024, when institutional policy mandated that patients discontinue GLP-1RAs for at least 14 days prior to painless EGD.
No Intervention: Observational Cohort
No Intervention: Observational Cohort
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No Intervention: Observational Cohort
No Intervention: Observational Cohort
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Complete clinical information available, including endoscopy report, age, sex, BMI, history of diabetes, prior gastric surgery, and gastrointestinal symptom
Exclusion Criteria
* History of gastric surgery (including ESD, gastrectomy, gastric bypass, etc.)
* Emergency endoscopy or non-elective procedures
* Missing key clinical information
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhijun Bao
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Danian Ji, M.D.
Role: STUDY_DIRECTOR
Huadong Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huadong hospital, Fudan university
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025K368
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.